Tag: Hilleman Labs
EVI & Hilleman Labs announce partnership to assess a new vaccine...
Funding from European and Developing Countries Clinical Trials Partnership (EDCTP) will allow testing of a novel whole-cell inactivated oral vaccine in clinical trials in Europe and Africa.................
Hilleman Labs licenses oral cholera vaccine ‘Hillchol’ to Bharat Biotech
Collaboration seeks to accelerate the development, licensure, manufacture and supply of an affordable, next-generation Cholera vaccine to support access in low and middle-income countries.................
Hilleman Labs partners with innovative ‘Future Vaccine Manufacturing Hub’
Hilleman Laboratories to collaborate with Imperial College London, Engineering and Physical Sciences Research Council (UK) and other premier international bodies towards low-cost vaccine manufacturing..............
Hilleman Labs completes phase I/II clinical trials of its cholera &...
The Hilleman Laboratories has successfully achieved the outcome of phase I/II clinical trial of its Oral Cholera Vaccine HillcholTM and Heat Stable Rotavirus Vaccine (HSRV)................
Hilleman Labs gets Indo-Swedish grant for developing oral cholera vaccine
The Oral Cholera Vaccine developed by Hilleman Laboratories is expected to make mass vaccination a reality in Cholera endemic zones due to ease of manufacturing and low cost...........
A step closer to a simpler & affordable oral cholera vaccine
After the successful toxicology studies, the promising Cholera vaccine “HILLCHOLTM is currently undergoing human clinical trial Phase I/II in collaboration with ICDDR, B and Incepta Vaccine Ltd in Bangladesh..........
Hilleman Lab partners with NICED, ICMR to develop Shigella vaccine
The Hilleman Laboratories on March 29, 2017 signed a memorandum of understanding (MoU) with NICED, ICMR to develop an indigenous Shigella vaccine.....
Novel vaccines from Hilleman Labs advance into clinical stage
It has initiated clinical trials for heat-stable Rotavirus vaccine and next-generation Cholera vaccine...